95 related articles for article (PubMed ID: 22181051)
1. Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies.
Burudpakdee C; Zhao Z; Munakata J; Gao S; Trochlil K; Barber B
J Med Econ; 2012; 15(2):371-7. PubMed ID: 22181051
[TBL] [Abstract][Full Text] [Related]
2. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
Yang H; Yu AP; Wu EQ; Yim YM; Yu E
J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
[TBL] [Abstract][Full Text] [Related]
3. The safety of monoclonal antibodies for treatment of colorectal cancer.
Berger MD; Lenz HJ
Expert Opin Drug Saf; 2016 Jun; 15(6):799-808. PubMed ID: 26982510
[TBL] [Abstract][Full Text] [Related]
4. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
[TBL] [Abstract][Full Text] [Related]
5. Costs of hospital events in patients with metastatic colorectal cancer.
Overbeek JA; Zhao Z; van Herk-Sukel MP; Barber BL; Gao S; Herings RM
J Med Econ; 2011; 14(5):656-61. PubMed ID: 21854190
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
7. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.
Saif MW; Longo WL; Israel G
Clin Colorectal Cancer; 2008 Mar; 7(2):144-8. PubMed ID: 18501075
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
9. Intricacies of bevacizumab-induced toxicities and their management.
Gressett SM; Shah SR
Ann Pharmacother; 2009 Mar; 43(3):490-501. PubMed ID: 19261963
[TBL] [Abstract][Full Text] [Related]
10. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012).
Ward A; Alvarez P; Vo L; Martin S
J Med Econ; 2014 Mar; 17(3):176-83. PubMed ID: 24410011
[TBL] [Abstract][Full Text] [Related]
11. Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.
Bilir SP; Ma Q; Zhao Z; Wehler E; Munakata J; Barber B
Am Health Drug Benefits; 2016 Jun; 9(4):203-13. PubMed ID: 27688833
[TBL] [Abstract][Full Text] [Related]
12. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
Hagiwara M; Hackshaw MD; Oster G
J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
[TBL] [Abstract][Full Text] [Related]
16. Managing patients treated with bevacizumab combination therapy.
Gordon MS; Cunningham D
Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
[TBL] [Abstract][Full Text] [Related]
17. Economic burden of toxicities associated with treating metastatic melanoma in eight countries.
Wehler E; Zhao Z; Pinar Bilir S; Munakata J; Barber B
Eur J Health Econ; 2017 Jan; 18(1):49-58. PubMed ID: 26721505
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
Spigel DR; Greco FA; Waterhouse D; Shipley D; Lane CM; Vazquez ER; Clark BL; Infante JR; Bendell JC; Burris HA; Hainsworth JD
Clin Adv Hematol Oncol; 2010 Jul; 8(7):480-5, 498. PubMed ID: 20864916
[TBL] [Abstract][Full Text] [Related]
19. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
20. Estimates of charges associated with emergency department and hospital inpatient care for opioid abuse-related events.
Chandwani HS; Strassels SA; Rascati KL; Lawson KA; Wilson JP
J Pain Palliat Care Pharmacother; 2013 Aug; 27(3):206-13. PubMed ID: 23879214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
